Concepedia

Author

Alexander Savchenko

Novartis (United States)ORCID

Also Known As

A P Savchenko, A. P. Savchenko, A. Savchenko, A.P. Savchenko, Alexander Savchenko

104

Publications

403

Citations

11

H-Index

9

Concepts

All Affiliations

Novartis (United States)Boehringer Ingelheim (Austria)Memorial Sloan Kettering Cancer CenterNovartis (Switzerland)University of California, Los Angeles
AS

About

Alexander Savchenko is an author at Novartis (United States) specializing in neuroendocrine tumors, surgical pathology, and surgical oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

61

2

Pathology

1

1

61

3

Surgical Oncology

1

1

61

4

Neuro-oncology

1

1

61

5

Adrenal Disease

1

1

61

Alexander Savchenko

×

10

Publications

364

Citations

10

H-Index

YearCitations

Discovery of Novel Spiro[3<i>H</i>-indole-3,2′-pyrrolidin]-2(1<i>H</i>)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2–p53 Interaction

Andreas Gollner, Dorothea Rudolph, Heribert Arnhof,

Journal of Medicinal Chemistry

2016

119

[Cancer of the adrenal cortex].

L V Uspenskiĭ, O P Kurguzov, Alexander Savchenko,

PubMed

1980

61

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

Ulrich Jaeger, Michael Bishop, Gilles Salles,

Blood

2020

31

Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses

Rohan Diwanji, Neil A. O’Brien, Jiyoung E. Choi,

Cancer Immunology Research

2023

30

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

Phillip M. Rappold, Lynda Vuong, Josef Leibold,

Cancer Discovery

2022

29

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

Hussein A. Tawbi, Caroline Robert, Jan C. Brase,

Journal for ImmunoTherapy of Cancer

2022

23

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

Michael P. Sanderson, Joshua F. Apgar, Pilar Garin‐Chesa,

Molecular Cancer Therapeutics

2015

20

PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays

Samuel J. Klempner, Eric S Cowden, Samuel Cytryn,

JCO Precision Oncology

2024

20

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

Jan C. Brase, Robert Walter, Alexander Savchenko,

Clinical Cancer Research

2021

16

A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses

Theresa A. Boyle, Gwendolyn P. Quinn, Matthew B. Schabath,

Cancer Medicine

2019

15

Page 1